Ranbaxy Consent Decree Includes Strict Requirements For Auditing Drug Applications
This article was originally published in PharmAsia News
Executive Summary
The agreement negotiated with U.S. FDA to resolve good manufacturing practice violations includes data integrity measures not commonly found in pharmaceutical GMP settlements, including auditing of almost all pending and approved drug applications and appointment of an independent data integrity expert.